Jaumot Frank E 4

What Happened Frank E. Jaumot, a director of Nutex Health, was granted 603 restricted stock units (RSUs) on July 14, 2025. The award was recorded as a derivative acquisition at a $0.00 per-unit price (no cash paid). The RSUs convert to common shares upon vesting; the filing shows the grant but not a cash value because future value depends on Nutex Health's stock price at vesting.

Key Details

• Transaction type and date: Grant of 603 RSUs on 2025-07-14 (code A — award/grant).
• Price reported: $0.00 per RSU (derivative award, no purchase price).
• Vesting: 100% vesting on 2026-07-14 (one-year cliff).
• Pro-rata vesting clause: If the director leaves without cause during the vesting period, the RSUs vest pro-rata for actual time served (per filing footnote).
• Shares owned after transaction: Not specified in the provided Form 4.
• Filing timeliness: The Form 4 was filed on 2026-02-09 reporting the 2025-07-14 grant, which is a late filing and delays public transparency about the insider award.

Context This was an equity award, not a purchase or sale. RSUs are a contingent right to receive shares upon vesting, so no shares were transferred to the director at grant. Such awards are commonly used for compensation and retention; their eventual value depends on Nutex Health’s share price at vesting.